Skip to content

Growing Tomorrow’s Biologics

At iBio, we’re pioneering the next generation of biopharmaceuticals using the fastpharmingSystem, our proprietary plant-based recombinant protein manufacturing platform.

The speed, safety and scalability inherent in the FastPharming Technology makes it ideal for rapidly advancing promising candidates from concept to clinic, while also enabling “greener” manufacturing. We seek to change the paradigm of drug development by reducing the time, costs, and scale-up issues associated with traditional mammalian cell culture production – thus making plant-based manufacturing the preferred choice for high quality biopharmaceutical development.

The FastPharming System has been successfully used to produce monoclonal antibodies, subunit vaccines, cytokines, and other recombinant proteins. Since we initiated our own proprietary drug development activities in 2020, we used the platform ourselves to scalably manufacture SARS-CoV-2 spike antigen candidates in just five weeks from sequence design – a speed that rivals that of mRNA platform technologies. We subsequently deployed FastPharming to advance a proprietary, second-generation COVID vaccine candidate while also rapidly creating our own pipeline of cancer drug candidates. In fact, we delivered six promising new additions to our oncology portfolio within just six months of establishing our discovery capabilities.

Plus, our novel Glycaneering Development Services℠ provide greater control over the glycosylation of complex biopharmaceuticals. Glycaneering can deliver molecules with greater Antibody-Dependent Cellular Cytotoxicity [ADCC], facilitating the creation of more potent anti-cancer therapeutics. We’ve demonstrated the quality and potency of Glycaneered molecules for our clients, not to mention strong data we’ve generated on plant-made rituximab. We’ve also used Glycaneering to afucosylate our novel anti-CD25 mAb as we convert it from CHO cell production to FastPharming.

We have two facilities; our San Diego, CA, site houses early-stage drug discovery and process development, and our Bryan/College Station, TX, facilty supports bioanalysis, protein characterization, and bioprocess services.

Our experienced team of scientists and engineers helps our clients leverage all of FastPharming’s advantages over mammalian cell culture. We’re experts in plant-based recombinant protein expression and purification process development and are happy to help drug developers avoid expensive media development, risks associated with animal-origin raw materials, master cell bank creation, and other issues associated with mammalian cell culture processes.

FastPharming Advantages

  • Faster: Greater speed-to-clinic by shaving months off of traditional mammalian-cell development times
  • Safer: Less contamination risk since mammalian viruses and prions can’t grow in plants
  • Eco-Friendly: Avoids plastic single-use disposables widely used with mammalian-cell biologics production
  • Easier: Avoids scaling issues moving to large bioreactors – just grow more plants
  • Better: Powerful, proprietary glycosylation controls for better performance and higher quality

Learn About FastPharming

Technology Applications

The FastPharming platform produces a variety of recombinant products including:

  • Biobetter and biosimilar antibodies
  • Antigens for subunit vaccine design
  • Virus-like particles (VLP)
  • Lysosomal enzymes
  • Blood factors, including cytokines, growth factors, and interleukins

Commitment to Sustainability

Like many other manufacturing businesses, biopharmaceutical production imposes demands on natural resources and the environment, urging us all to think about the sustainability of future requirements for production and global supply.

In fact, one study states that the drug industry’s emission intensity in 2015 was 55% more than the auto industry1.

We’re pioneering sustainable biomanufacturing with the FastPharming System®. Our upstream raw materials include seeds, purified water/nutrients and photons. Compare that with traditional single-use mammalian cell culture systems that make extensive use of plastic consumables, energy-intensive water (water-for-injection [WFI]), filters, and upwards of 2,000 liter scale bioreactor operations requiring cell culture media consumables, energy to power the mixing, anti-foaming agents, and more.

We offer a more sustainable option for innovators looking to develop their process – an early decision that has a long-term impact. Making the choice today to use our plant-based expression system – delivering a greener, more sustainable process – is a decision that will have a lasting impact for decades as a product moves all the way from concept to commercial production.

1. Belkhir, L., et. al. (2018) “Carbon footprint of the global pharmaceutical industry and relative impact of its major players”. J Cleaner Production 214:185-194

Commitment to Quality Biologics

The Quality Department at iBio is staffed with highly motivated and skilled professionals who are knowledgeable in biologics development and manufacturing.  Key elements of our quality program include:

  • A fully integrated Quality Management System (QMS)
  • Robust process/product control systems
  • Comprehensive compliance programs

iBio’s quality systems are designed to comply with cGMP’s as well as ex-US regulatory requirements.

iBio’s Quality Policy

iBio is dedicated to maintaining the effectiveness of the quality system through robust process management and quality oversight, compliance with all applicable regulatory requirements, and meeting or exceeding customer expectations by delivering quality products and services.

Our Team

Martin Brenner headshot
Robert Lutz
Peter Kipp headshot
Dillon Phan headshot

Partners

  • CC-Pharming
  • The Texas A&M AgriLife
  • The Texas A&M University System
  • SAFI
  • EdgePoint AI
  • IDRI
  • RubrYc Therapeutics
    RubrYc Therapeutics
  • FairJourney Biologics
    FairJourney Biologics
Top